Expertise in
6
conditions

Dr. Rachel L. Theriault

Oncology
Fort Worth, TX 
Accepting New Patients
Offers Telehealth
Expertise in
6
conditions
Fort Worth, TX 

Overview

Rachel Theriault is an Oncologist practicing medicine in Fort Worth, Texas.

Dr. Theriault is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Dr. Theriault is board certified in Medical Oncology- American Board Of Internal Medicine, Medical Oncology- American Board Of Internal Med/Medical Oncology, and Internal Medicine- American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 5 clinical trials. Dr. Theriault is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Board Certifications

Medical Oncology- American Board Of Internal Medicine
Medical Oncology- American Board Of Internal Med/Medical Oncology
Internal Medicine- American Board Of Internal Medicine

Fellowships

Hematology and Medical Oncology, University of Texas MD Anderson Cancer Center - 2011

Hospital Affiliations

Baylor Scott & White All Saints Medical Center - Fort Worth
Baylor Scott And White All Saints Medical Center
Texas Health Harris Methodist Hospital Southwest F
Medical City Alliance
Texas Health Harris Methodist Fort Worth

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cook Children's Health Plan
  • MANAGED MEDICAID PLAN
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
Fort Worth, TX 76104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival
ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival
Enrollment Status: Active_not_recruiting
Publish Date: July 15, 2026
Intervention Type: Drug, Procedure, Other
Study Phase: Not Applicable
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Unknown
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
View 3 Less Clinical Trials

6 Total Publications

Evaluation of data analysis pipelines for ambient ionization mass spectrometry: Bridging analytical chemistry and data science.
Evaluation of data analysis pipelines for ambient ionization mass spectrometry: Bridging analytical chemistry and data science.
Journal: Analytica chimica acta
Published: March 02, 2026
Similar Doctors
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Referral may be required

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (28.4 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Awan is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
14
conditions
Expertise in
14
conditions
Referral required
Before you request

Texas Oncology, P.A.

3410 Worth Street, Suite 400, 
Dallas, TX 
 (31.6 miles away)
214-370-1000
Experience:
44+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Inflammatory Breast Cancer, and Tissue Biopsy. Dr. O'shaughnessy is board certified in Medical Oncology- American Board Of Internal Medicine, Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. Dr. O'shaughnessy is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Office

2201 Inwood Rd, 
Dallas, TX 
 (28.4 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans Hammers is an Oncologist practicing medicine in Dallas, Texas. Dr. Hammers is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Wilms Tumor, Nephrectomy, and Thrombectomy.

Frequently Asked Questions about Dr. Rachel L. Theriault

How do I make an appointment with Dr. Rachel L. Theriault?

You can book an appointment with Dr. Rachel L. Theriault by calling their office at 817-413-1500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rachel L. Theriault a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rachel L. Theriault is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rachel L. Theriault specialize in?

While Dr. Rachel L. Theriault is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Rachel L. Theriault participate in research or clinical trials?

Yes. Dr. Rachel L. Theriault has published 6 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Rachel L. Theriault's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rachel L. Theriault accept my insurance?

Dr. Rachel L. Theriault accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 817-413-1500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Theriault's expertise for a condition
ConditionClose
    View All 80 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile